Search Results - "Foley, Peter"

Consensus on the Use of JAKinibs for Atopic Dermatitis in Australia and New Zealand. An eDelphi by the Australasian Medical Dermatology Group.

Authors: Rademaker, Marius Foley, Peter Armour, Katherine et al.

Source: Australasian Journal of Dermatology. Aug2025, Vol. 66 Issue 5, pe287-e296. 10p.

Wolf's Isotopic Response: A Rare Case of Terra Firma‐Forme Dermatosis on Resolved Psoriatic Plaques.

Authors: Larney, Conor Foley, Peter A. Lee, Senhong

Source: Australasian Journal of Dermatology. Jun2025, Vol. 66 Issue 4, pe232-e234. 3p.

Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies – Considerations for paediatric patients.

Authors: Foley, Peter Mahar, Patrick D. Smith, Saxon D. et al.

Source: Australasian Journal of Dermatology. Sep2024, Vol. 65 Issue 6, pe134-e144. 11p.

Real World Side‐Effects of Dupilumab: A Narrative Review.

Authors: Larney, Conor Foley, Peter Wu, Jason et al.

Source: Australasian Journal of Dermatology. Sep2025, Vol. 66 Issue 6, pe324-e334. 11p.

Author Index.

Source: Experimental Dermatology. Nov2021 Supplement S1, Vol. 30, p44-47. 4p.

Efficacy and Safety of Switching From Intravenous to Subcutaneous Infliximab for Psoriasis: A Case Series.

Authors: Larney, Conor Foley, Peter Gebauer, Kurt et al.

Source: Australasian Journal of Dermatology. Mar2025, Vol. 66 Issue 2, pe49-e51. 3p.

Dupilumab for chronic actinic dermatitis: A case series and review of the literature.

Authors: Holmes, Zachary Foley, Peter Baker, Chris et al.

Source: Australasian Journal of Dermatology. May2024, Vol. 65 Issue 3, p287-291. 5p.

Safety and Immunogenicity of Live Attenuated Vaccine Administration in Patients Undergoing Treatment With Dupilumab and Apremilast: A Systematic Review.

Authors: Larney, Conor Foley, Peter Daniel, Benjamin S.

Source: Australasian Journal of Dermatology. Jun2025, Vol. 66 Issue 4, p199-203. 5p.

Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies – Adult patients.

Authors: Foley, Peter Gebauer, Kurt Sullivan, John et al.

Source: Australasian Journal of Dermatology. Nov2023, Vol. 64 Issue 4, p476-487. 12p.

Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis.

Authors: Armstrong, April W. Foley, Peter Liu, Yan et al.

Source: Dermatology & Therapy. Sep2024, Vol. 14 Issue 9, p2577-2589. 13p.

Upadacitinib for Chronic Actinic Dermatitis: A Case Report and Literature Review of JAK Inhibitor Use for Recalcitrant Disease.

Authors: Holmes, Zachary Larney, Conor Foley, Peter et al.

Source: Australasian Journal of Dermatology. May2025, Vol. 66 Issue 3, p169-171. 3p.

Modified Delphi Consensus Recommendations for the Management of Psoriasis in Asia–Pacific.

Authors: Baek, Yoo Sang Choon, Siew Eng Foley, Peter Anthony et al.

Source: Dermatology & Therapy. Jul2026, p1-20. 20p.

A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence.

Authors: Silverberg, Jonathan I. Irvine, Alan D. Foley, Peter et al.

Source: Dermatology & Therapy. Jun2026, p1-20. 20p.

Eight‐Year Experience of Hedgehog Pathway Inhibitors at Three Tertiary Referral Centres in the Australian State of Victoria.

Authors: Gan, Christian Manuelpillai, Nicholas Foley, Peter et al.

Source: Australasian Journal of Dermatology. Aug2025, Vol. 66 Issue 5, pe297-e301. 5p.

Barriers to the introduction of novel advanced targeted treatments for Australian dermatology patients: Are skin diseases symptomatic of a systemic healthcare problem?

Authors: Mahar, Patrick David Crothers, Anna Foley, Peter et al.

Source: Australasian Journal of Dermatology. Sep2024, Vol. 65 Issue 6, pe164-e167. 4p.

Dupilumab‐associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting.

Authors: Foley, Peter Kerdraon, Yves A. Hogden, John P. et al.

Source: Australasian Journal of Dermatology. Nov2022, Vol. 63 Issue 4, p421-436. 16p. 2 Color Photographs, 2 Diagrams, 2 Charts.

Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21‐month analysis in Australian routine clinical practice (SUSTAIN study).

Authors: Foley, Peter Manuelpillai, Nick Dolianitis, Con et al.

Source: Australasian Journal of Dermatology. Aug2022, Vol. 63 Issue 3, p303-311. 9p. 1 Diagram, 2 Charts, 3 Graphs.

Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study.

Authors: Foley, Peter Spelman, Lynda Murrell, Dedee F. et al.

Source: Australasian Journal of Dermatology. Aug2022, Vol. 63 Issue 3, p312-320. 9p. 1 Diagram, 2 Charts, 3 Graphs.

Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study.

Authors: Foley, Peter Tsai, Tsen-Fang Rodins, Karl et al.

Source: Dermatology & Therapy. Feb2022, Vol. 12 Issue 2, p511-527. 17p.

Tildrakizumab use for recalcitrant pityriasis rubra pilaris.

Authors: Holmes, Zachary Goh, Michelle S. Foley, Peter et al.

Source: Australasian Journal of Dermatology. Aug2024, Vol. 65 Issue 5, p476-479. 4p.